Advertisement

Journal of Neural Transmission

, Volume 103, Issue 6, pp 749–757 | Cite as

Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine

  • L. Naylor
  • B. Dean
  • K. Opeskin
  • G. Pavey
  • C. Hill
  • N. Keks
  • D. Copolov
Biological Psychiatry

Summary

[3H]paroxetine binding to membrane from hippocampus, obtained at autopsy, from 24 schizophrenic and 24 non-schizophrenic subjects has been measured. The affinity of [3H]paroxetine binding to hippocampal membrane was decreased in subjects with schizophrenia (Kd=0.50 ± 0.04 vs. 0.24 ± 0.02nM; mean ± S.E.M. p < 0.001) but was not different in schizophrenic subjects who had or had not committed suicide (Kd=0.50 ± 0.07 vs. 0.50 ± 0.04nM). The density of [3H]paroxetine binding sites did not differ between the schizophrenic and non-schizophrenic subjects. For the schizophrenic subjects, there was no relationship between ante-mortem neuroleptic drug treatment and [3H]paroxetine binding to the hippocampal membrane. Finally, this study has shown that neuroleptic drug treatment of rats does not alter [3H]paroxetine binding to the hippocampal membranes. Thus, it would seem that the changes in the affinity of [3H]paroxetine binding to the hippocampus of schizophrenic subjects are not likely to be due to neuroleptic drug treatment but may be involved in the pathology of the illness.

Keywords

[3H]paroxetine hippocampus schizophrenia neuroleptic drugs suicide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersson A, Sundman I, Marcusson J (1992) Age stability of human brain 5-HT terminals studied with [3H]paroxetine binding. Gerontology 38: 127–132PubMedGoogle Scholar
  2. Arora RC, Meltzer HY (1991) Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm [Gen Sect] 85: 19–29Google Scholar
  3. Bennett JP, Enna SJ, Byland DB, Gillin JC, Wyatt RJ, Snyder SH (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36: 927–934PubMedGoogle Scholar
  4. Dean B, Opeskin K, Pavey G, Naylor L, Hill C, Keks N, Copolov DL (1995) [3H]Paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem 64: 1197–1202PubMedGoogle Scholar
  5. Habert E, Graham D, Tahraoui L, Claustre Y, Langer S (1985) Characterization of [3H]paroxetine binding to rat cortical membrane. Eur J Pharmacol 118: 107–114PubMedGoogle Scholar
  6. Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, Nishino N, Tanaka C (1993) Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112: 35–39Google Scholar
  7. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1994) Serotonin uptake sites and serotonin receptors are altered in limbic system of schizophrenics. Neuropsychopharmacology 8: 315–336Google Scholar
  8. Kerwin RW (1994) The new atypical antipsychotics. Br J Psychiatry 164: 141–148PubMedGoogle Scholar
  9. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleiman JF (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. Arch Gen Psychiatry 50: 810–818PubMedGoogle Scholar
  10. Lesen KP, Wolozin BL, Murphy DL, Riederer P (1993) Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60: 2319–2322PubMedGoogle Scholar
  11. Maguire K, Tuckwell V, Pereira A, Dean B, Singh B (1993) Significant correlation between14C-5-HT uptake by and3H-paroxetine binding to platelets from healthy volunteers. Biol Psychiatry 34: 356–360PubMedGoogle Scholar
  12. Marcusson JO, Backstrom I, Ross SB (1988) Characterization of [3H]paroxetine binding in rat brain. J Neurochem 50: 1783–1790PubMedGoogle Scholar
  13. Mellerup ET, Plenge P (1986) High affinity binding of3H-paroxetine and3H-imipramine to rat neuronal membranes. Psychopharmacol 89: 436–439PubMedGoogle Scholar
  14. Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21: 1407–1414PubMedGoogle Scholar
  15. Plenge P, Mellerup ET (1985) Antidepressive drugs can change the affinity of [3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes. Eur J Pharmacol 119: 1–8PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • L. Naylor
    • 1
    • 2
  • B. Dean
    • 1
    • 2
  • K. Opeskin
    • 1
    • 3
  • G. Pavey
    • 1
  • C. Hill
    • 1
  • N. Keks
    • 1
    • 4
  • D. Copolov
    • 1
    • 2
  1. 1.The Rebecca L. Cooper LaboratoriesThe Mental Health Research Institute of VictoriaUSA
  2. 2.The NH & MRC Schizophrenia Research UnitRoyal Park Psychiatric HospitalParkville
  3. 3.The Victorian Institute of Forensic PathologySouth Melbourne
  4. 4.The Department of PsychiatryThe Alfred HospitalPrahranAustralia

Personalised recommendations